Research Topic: psychedelic therapy

Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon

mycolabadmin

Psilocybin, the active compound in certain mushrooms, shows promise as a treatment for depression and anxiety in cancer patients, particularly those nearing end of life. Oregon legalized supervised psilocybin therapy in 2020, making it the first U.S. state to do so. While clinical research shows the treatment can rapidly reduce depression and improve quality of life, the actual rollout has faced challenges including regulatory hurdles, lack of professional standards, and unequal geographic access.

Read More »

Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial

mycolabadmin

Researchers surveyed chronic pain patients about their willingness to participate in a trial testing psilocybin (a compound from magic mushrooms) as a pain treatment. About 77% of patients were interested in participating. Interestingly, patients who had previously used psychedelics were much more willing to join the trial. Common reasons for wanting to participate included needing new pain treatments, while concerns about side effects and practical difficulties like attending multiple appointments discouraged others.

Read More »
Scroll to Top